# Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

> **NCT05407584** · PHASE2 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 56 (estimated)

## Conditions studied

- PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

## Interventions

- **DRUG:** Orevogomab+PLD
- **DRUG:** Orevogomab+Paclitaxel

## Key facts

- **NCT ID:** NCT05407584
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-05
- **Primary completion:** 2024-05
- **Final completion:** 2024-11
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2023-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05407584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05407584, "Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05407584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*